Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid

Shah, Sachin; Jean, Gary W.; Keisner, Sidney V; Ussery, Sarah M. Gressett; Dowell, Jonathan E.

doi:10.1007/s00520-010-1067-7

Cited by 13 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Due to concerns of renal toxicity, dosage adjustment in patients with existing mild to moderate renal insufficiency [creatinine clearance (CrCl) 30 but <60 mL/min] treated with zoledronic acid is recommended [43]. For CrCl of 50-60 mL/min, 40-49 mL/min and 30-39 mL/min, the dose of zoledronic acid should be reduced to 3.5 mg, 3.3 mg, and 3 mg, respectively [44].…”

Section: Do Tackle Hypercalcemia Aggressivelymentioning

confidence: 99%

Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma

et al. 2015

View full text Add to dashboard Cite

In the era of novel biological agents, multiple myeloma (MM) is often approached as a chronic condition. While survival continues to improve, population‐level data indicate that early mortality remains a substantial barrier to advances in MM outcomes. Here we provide “do's and don'ts” management recommendations that may minimize the risk of early mortality and ensure that patients have the opportunity to benefit from the long term impact of new effective MM agents. Such recommendations encompass the early introduction of novel agents even in the presence of comorbidities and advanced age and aggressive management of MM‐related complications. Am. J. Hematol. 91:101–108, 2016. © 2015 Wiley Periodicals, Inc.

show abstract

Section: Do Tackle Hypercalcemia Aggressivelymentioning

confidence: 99%

Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…However, ZOL is cleared by renal filtration, and the dosing adjustment is designed to maintain exposure to ZOL among patients with renal impairment with the goal of maintaining treatment efficacy. Indeed, the modified dosing scheme of ZOL in patients with impaired renal function was recently reported to produce similar SRE-preventing efficacy compared with the standard dose in patients with normal renal function 30 . Also, no adjustment was made for the number of patients with each type of cancer, as the likelihood of SREs differs among cancer types and disparate numbers of patients in each cancer type were analyzed in this study.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid

Henk

Teitelbaum

Kaura

2012

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…Las complicaciones renales parecen ser más frecuentes en los pacientes con enfermedad renal basal (3,5) . En pacientes con filtración glomerular inferior a 30 ml/min es aconsejable reducir la dosis a la mitad, porque hay una menor eliminación.…”

Section: Discussionunclassified

“…La retención de hueso para el AZ en pacientes con metástasis óseas oscila entre 25% y 93% (3) y es el bifosfonato más potente (5,9) . La inhibición potente de osteoclastos inducida por el AZ reduce la contribución de la resorción ósea a la homeostasis del calcio y puede aumentar el hiperparatiroidismo secundario de pacientes con cáncer de próstata (9) .…”

Section: Discussionunclassified

See 1 more Smart Citation

Caso 4-2014: Femenina 49 Años Con Metástais Óseas Y Hemodiálisis: Uso De Ácido Zoledrónico

Méndez

Chacón²,

Roel³

2014

RC_UCR-HSJD

View full text Add to dashboard Cite

RESUMENSe psenta el caso de una paciente con cáncer de cérvix con metástasis óseas y terapia renal sustitutiva (hemodiálisis, HD) a que se le trató con ácido zoledrónico (AZ), gabapentina y morfina. El AZ es el bifosfonato nitrogenado más potente. No hay datos suficientes para recomendar cualquier dosis de bifosfonatos por vía endovenosa en pacientes en HD crónica. En los pacientes portadores de alguna neoplasia con metástasis a hueso y recibiendo HD puede utilizarse el AZ IV a la mitad de la dosis habitual, en una infusión lenta el día previo a la HD. PALABRAS CLAVE ÁcidoZoledrónico. Metástasis óseas. Hemodiálisis. ABSTRACTWe report the case of a 49-years old female patient with cervix cancer, bone metastases and renal replacement therapy (hemodialysis, HD) that was treated with zoledronic acid (AZ), gabapentin and morphine. The AZ is the most potent nitrogen-containing bisphosphonate. There are insufficient data to recommend any dose of intravenous (IV) bisphosphonates in chronic HD patients. In patients with cancer, bone metastases and receiving HD; can be used AZ IV using half the usual dose in slow infusion on the day before the HD KEY WORDSZoledronic acid. Bone metastases. Hemodialysis.

show abstract

Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid

Abstract: The incidence of ARF is similar between patients in the normal group and impaired group when the ZA dose is renally adjusted.

Cited by 13 publications

References 14 publications

Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma

Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma

Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid

Caso 4-2014: Femenina 49 Años Con Metástais Óseas Y Hemodiálisis: Uso De Ácido Zoledrónico

Contact Info

Product

Resources

About